Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Jun 10, 2021
Neuren to present at MST Access investor conference
Jun 10, 2021
Update - Annual General Meeting 2021
Jun 01, 2021
Positive FDA meetings enable INDs for three Phase 2 trials
May 21, 2021
Virtual AGM online guide
May 21, 2021
Notice of Annual General Meeting/Proxy Form
Apr 29, 2021
New patent issued to 2032 for Neuren's trofinetide in Canada
Apr 27, 2021
Appendix 4G
Apr 27, 2021
Annual Report to shareholders
Apr 22, 2021
Quarterly report and cash flow statement for Q1 2021
Mar 23, 2021
Investor presentation, 23 March 2021
Previous
1
2
3
4
5
6
Next
